SHANGHAI (Reuters) - Chinese regulators have approved Pfizer Inc’s blockbuster vaccine Prevenar 13, the U.S. drugmaker said on Wednesday, a breakthrough for the firm after it was forced to shut its vaccine business in China last year.
Prevenar - one of Pfizer’s top selling products - is used primarily for infants to help prevent pneumococcal disease, a bacterial infection that can lead to illnesses such as pneumonia, meningitis and sepsis.
Pfizer shuttered its China vaccines business after a license for an earlier version of Prevenar was not renewed in 2015. Foreign drugmakers face growing difficulties obtaining approvals for medicines in China, the world’s No. 2 drug market.
The U.S. firm said it had received approval from the China Food and Drug Administration (CFDA) to market Prevenar 13 to infants and children aged between 6 weeks to 15 months.
“We applaud the efforts of CFDA and other relevant Chinese government agencies to bring new medicines and vaccines to the Chinese healthcare system,” Wu Xiaobin, president of Pfizer China, said in a statement.
The firm aims to make the vaccine available in China within the earliest possible timeframe, but there was no set date, said Pfizer spokeswoman Trupti Wagh.
“We have just received the approval and we are working through the timing of our launch,” she said in an email.
Global revenues from the Prevenar family of products, which includes Prevenar 13, were $6.2 billion last year, up 40 percent from 2014, Pfizer said in its annual report. Prevenar saw “strong operational growth” in China before losing approval.
Reporting by Adam Jourdan; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.